Immunitor unveils breakthrough immunotherapy to treat tuberculosis in as short as one month
Immunitor Inc., commercial-stage biotech company, is pleased to announce the publication of positive results from the randomized, placebo-controlled Phase III clinical trial for Tubivac (V7), the first-in-class, orally-available therapeutic vaccine used as an immune adjunct for the chemotherapy of tuberculosis (TB). VANCOUVER, BRITISH COLUMBIA (PRWEB) FEBRUARY 01, 2020 Immunitor Inc., commercial-stage[…]
Read more